The difference between information and
expert, data-driven actionable intelligence

 

November 2016

Welcome to the November 2016 issue of CMC Market Outlook

This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.

Enjoy the November issue!

The PharmSource Team

 

Trial Registrations Reflect Improved Funding

The impact of the strong funding environment for emerging bio/pharma companies is being reflected in new clinical trial starts. An analysis of new clinical trial registrations in the clinicaltrials.gov database indicates that Phase I and II trial starts for which an emerging bio/pharma company is the sponsor or principal collaborator were up 65% in the first half of 2012 versus the first half of 2016.

The jump in trial registrations is closely correlated to the improved funding environment that emerging bio/pharma companies have enjoyed in recent years. External funding for emerging biopharma companies in 2015, i.e., the funding year immediately preceding the 2016 trial registrations, was more than… read on
 

Five Themes That Will Drive the CMO Industry

by Jim Miller, President

Trade shows provide a good opportunity to gauge the temperature of the contract development and manufacturing organization (CDMO) industry and find out which trends and concerns are most on people’s minds. Five themes really stood out from conversations at the CPhI Worldwide event held in Barcelona in October 2016.

Mergers and acquisitions continue to create the most buzz around the industry, and speculating about which contract manufacturing organizations (CMOs) are the next target or the next acquirer is a favorite topic of conversation. The industry certainly seems set up for… read on
 

How big is the market for…?

This is a handy guide to frequently requested data about the bio/pharma contract services industry.

The market for overall bio/pharmaceutical outsourced development spending:

Market Growth Source
2016: $26 billion
2019: $31 billion
Medpace
Presentation at Baird Global Healthcare Conference
September 2016

Read more about the size of the contract services market for various segments.
 

Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars

This data-rich report, Bio/Pharma CapEx Trends 2016, identifies 3 indicators of what’s ahead for your business:

1. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

2. Bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years.

3. Based on recent capital expenditure trends, learn why bio/pharma companies would rather “make than buy.”


 

PharmSource Strategic Advantage


Let PharmSource be your market intelligence guide.

PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.

See for yourself how this resource gives you vital tools for understanding the industry.

To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / +1-703-383-4903, ext. 112 (ET USA).